IQVIA Holdings Inc.
IQV Real Time Price USD$IQV is featured in our Rob Bresnahan strategy.
All StrategiesRecent trades of IQV by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes in IQV holdings by institutional investors
Quarterly net insider trading by IQV's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
-
$60,000 Oct 17, 2025 Issue: Health Issues
-
$60,000 Jul 21, 2025 Issue: Health Issues
-
$60,000 Apr 21, 2025 Issue: Health Issues
-
$60,000 Mar 07, 2025 Issue: Health Issues
-
$60,000 Jan 21, 2025 Issue: Health Issues
-
$60,000 Oct 21, 2024 Issue: Health Issues
-
$60,000 Apr 22, 2024 Issue: Health Issues
-
$60,000 Jan 22, 2024 Issue: Health Issues
-
$60,000 Oct 20, 2023 Issue: Health Issues
-
$60,000 Jul 20, 2023 Issue: Health Issues
-
$60,000 Jan 20, 2023 Issue: Health Issues
-
$60,000 Oct 19, 2022 Issue: Health Issues
-
$60,000 Jul 20, 2022 Issue: Health Issues
-
$30,000 Apr 20, 2022 Issue: Health Issues
IQV Estimated quarterly lobbying spending
IQV Revenue by Segment or Geography
New IQV patent grants
-
Patent Title: System and method for detecting drug adverse effects in social media and mobile applications data Oct. 14, 2025
-
Patent Title: Management and tracking solution for specific patient consent attributes and permissions Jul. 22, 2025
-
Patent Title: Automation-enhanced translation workflow Jun. 24, 2025
-
Patent Title: System and method for creation of persistent patient identification Jun. 03, 2025
-
Patent Title: Multi-agent data asset synthesis system Jun. 03, 2025
-
Patent Title: System and method for creation of persistent patient identification May. 27, 2025
-
Patent Title: System and method for phenotype vector manipulation of medical data May. 13, 2025
-
Patent Title: Matching service requester with service providers Apr. 29, 2025
-
Patent Title: Gxp artificial intelligence / machine learning (ai/ml) platform Apr. 08, 2025
-
Patent Title: Digital label management Apr. 08, 2025
-
Patent Title: Requirements to test system and method Apr. 08, 2025
-
Patent Title: Machine reasoning as a service Feb. 18, 2025
-
Patent Title: System and method for creation of persistent patient identification Nov. 26, 2024
-
Patent Title: Optimization of investigator and site location identification Oct. 01, 2024
-
Patent Title: Automated clinical concept mapping using snomed Sep. 24, 2024
-
Patent Title: System and method for providing multi-layered access control Sep. 10, 2024
-
Patent Title: System and method to regularize cancer treatment data for systematic recording Sep. 10, 2024
-
Patent Title: Computing platform for establishing referrals Sep. 03, 2024
-
Patent Title: Lifelong machine learning (lml) model for patient subpopulation identification using real-world healthcare data Sep. 03, 2024
-
Patent Title: System and method for enhanced distribution of data to compute nodes Jul. 30, 2024
-
Patent Title: Synthesizing complex population selection criteria Jun. 11, 2024
-
Patent Title: Management and tracking solution for specific patient consent attributes and permissions Jun. 04, 2024
-
Patent Title: System and method for timely multi-channel notification of treatment May. 28, 2024
-
Patent Title: Systems and methods for streaming normalized clinical trial capacity information Apr. 16, 2024
-
Patent Title: Automated clinical concept mapping using snomed Apr. 16, 2024
-
Patent Title: Mapping and display for evidence based performance assessment Apr. 02, 2024
-
Patent Title: Methods and systems for predictive clinical planning and design Mar. 26, 2024
-
Patent Title: Reconciliation of data across distinct feature sets Mar. 05, 2024
-
Patent Title: Professional network-based identification of influential thought leaders and measurement of their influence via deep learning Mar. 05, 2024
-
Patent Title: System and method for timely notification of treatment Feb. 27, 2024
-
Patent Title: Machine reasoning as a service Feb. 20, 2024
-
Patent Title: Classification code parser for identifying a classification code to a text Jan. 30, 2024
-
Patent Title: Automated classification and interpretation of life science documents Jan. 09, 2024
-
Patent Title: System and method for merging slowly changing data Jan. 09, 2024
-
Patent Title: System and method for genomic data analysis Jan. 02, 2024
-
Patent Title: System and method for enhanced curation of health applications Nov. 14, 2023
-
Patent Title: Requirements to test system and method Nov. 07, 2023
-
Patent Title: Automated translation of subject matter specific documents Aug. 22, 2023
-
Patent Title: System and method for detecting drug adverse effects in social media and mobile applications data May. 16, 2023
-
Patent Title: Pre-computing data metrics using neural networks Apr. 18, 2023
-
Patent Title: System for predicting patient health conditions Apr. 04, 2023
-
Patent Title: System and method for enhanced distribution of data to compute nodes Apr. 04, 2023
-
Patent Title: System and method for longitudinal non-conforming medical data records Mar. 28, 2023
-
Patent Title: Digital label management Mar. 28, 2023
-
Patent Title: Predictive system for generating clinical queries Mar. 28, 2023
-
Patent Title: Machine reasoning as a service Mar. 21, 2023
-
Patent Title: Classification code parser Feb. 21, 2023
-
Patent Title: System and method for phenotype vector manipulation of medical data Feb. 07, 2023
-
Patent Title: Automated classification and interpretation of life science documents Feb. 07, 2023
-
Patent Title: System and method for master data management Oct. 18, 2022
Federal grants, loans, and purchases
Estimated quarterly amount awarded to IQV from public contracts
Recent insights relating to IQV
Recent picks made for IQV stock on CNBC
ETFs with the largest estimated holdings in IQV
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $IQV stock a Buy, Sell, or Hold?
- What is the price target for $IQV stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $IQV stock?
- Who owns the most shares of $IQV stock?
- What funds own $IQV stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view IQV Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Iqvia is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
- Address Durham, NC
- Market Cap 38.3 billion
- Employees 91,000
- Industrial Classification Services-Commercial Physical & Biological Research